

1 **A simple method for deriving functional MSCs and applied for osteogenesis**  
2 **in 3D scaffolds**

3

4 Lijin Zou <sup>1, 2, #</sup>, Yonglun Luo <sup>3, #, \*</sup>, Muwan Chen <sup>1, 4, #</sup>, Gang Wang <sup>5, 6, #</sup>, Ming Ding  
5 <sup>7</sup>, Charlotte Christie Petersen <sup>3, 8</sup>, Ran Kang <sup>1</sup>, Frederik Dagnaes-Hansen <sup>3</sup>,  
6 Yuanlin Zeng <sup>2</sup>, Nonghua Lv <sup>2</sup>, Qing Ma <sup>5, 6</sup>, Dang Q.S.Le <sup>1</sup>, Flemming  
7 Besenbacher <sup>4</sup>, Lars Bolund <sup>3</sup>, Thomas G. Jensen <sup>3</sup>, Jørgen Kjems <sup>4</sup>, William T.  
8 Pu <sup>5, 6</sup>, Cody Bünger <sup>1</sup>

9

10 1 Orthopaedic Research Laboratory, Department of Orthopaedics, Aarhus  
11 University Hospital, Aarhus, DK

12 2 Department of Surgery, The First Affiliated Hospital of Nanchang University,  
13 Nanchang, CN

14 3 Department of Biomedicine, Aarhus University, 8000, Aarhus, DK

15 4 Interdisciplinary Nanoscience Center, Aarhus University, Aarhus, DK

16 5 Department of Cardiology, Boston Children's Hospital, MA, USA

17 6 Harvard Stem Cell Institute, Harvard University, Cambridge, MA, USA

18 7 Orthopaedic Research Laboratory, Department of Orthopaedics &  
19 Traumatology, Odense University Hospital, Institute of Clinical Research,

20 University of Southern Denmark, 5000 Odense C, Denmark

21 8 The FACS Core Facility, Faculty of Health, Aarhus University, Aarhus, Denmark

22 # The authors contributed equally to this work.

23

24 \*Correspondence:

25 **Yonglun Luo**, Department of Biomedicine, Aarhus University,  
26 8000, Aarhus, Denmark. Phone 0045 8716 8394; Fax: 0045 8612 8316; Email:  
27 ALUN@HUM-GEN.AU.DK

28

## 29 **Supplementary Materials and Methods**

### 30 ***1. Production of mRNA reprogramming mRNA cocktail***

31 The transcript templates for reprogramming factors Oct4, Sox2, Klf4, c-Myc, Lin28  
32 were generated from the plasmids (from Addgene) by adding 120 T through tail  
33 PCR. Synthetic mRNA was generated in IVT reactions using a 4:1 ratio of ARCA  
34 cap analog to GTP to give a high percentage of capped transcripts. Complete  
35 substitution of 5m-CTP for CTP and Pseudo-UTP for UTP in the nucleotide  
36 triphosphate (NTP) mix was employed to reduce the immunogenicity of the RNA  
37 products. Cap analog and modified NTPs were purchased from Trilink  
38 Biotechnologies. A 2.5X NTP mix was prepared  
39 (ARCA:ATP:5m-CTP:GTP:Pseudo-UTP at 15:15:3.75:3.75:3.75 mM) to replace  
40 the standard NTPs provided with the MEGAscript T7 Kit (Ambion) used to perform  
41 IVT reactions. Each 40 uL IVT reaction comprised 16 uL NTP mix, 4 uL 10X T7  
42 Buffer, 16 uL DNA template and 4 uL T7 polymerase. Reactions were incubated  
43 4–6 hours at 37°C and treated with 2 uL TURBO DNase for a further 15 minutes  
44 at 37°C before being purified on MEGAclean (Ambion) spin columns; the RNA  
45 products being eluted in a volume of 100 uL. To remove immunogenic 5'  
46 triphosphate moieties from uncapped transcripts, 10 uL of Antarctic Phosphatase

47 reaction buffer and 3 uL of Antarctic Phosphatase (NEB) were added to each prep.  
48 Phosphatase reactions were incubated for 30 minutes at 37°C and the IVT  
49 products were repurified. RNA yield was quantified by Nanodrop technology  
50 (Thermo Scientific), and the preps were subsequently adjusted to a standardized  
51 working concentration of 100 ng/uL by addition of TE pH 7.0 (Ambion). IVT  
52 product quality was checked with an RNA bioanalyzer. Cocktails were assembled  
53 by pooling preps representing the various RFs in the desired stoichiometric ratios.  
54 All reprogramming factors being equimolar except for Oct4 (3X molar  
55 concentration).

56

## 57 ***2. Molecular Characterization of iPSCs***

58 Cells were fixed in 4% paraformaldehyde for 20 min. Washed cells were treated  
59 with 0.2% Triton X (Sigma) in PBS for 30 min. Cells were blocked with 3% BSA  
60 (Invitrogen) and 5% donkey serum (Sigma) for 2 hr at RT. Cells were stained in  
61 blocking buffer with primary antibodies at 4°C overnight. Cells were washed and  
62 stained with secondary antibodies) in blocking buffer for 3 hr at 4°C or for 1 hr at  
63 RT, protected from light. The images were taken with a LA confocal microscope.

64

## 65 ***3. Teratoma formation***

66 Adult SCID mice were anesthetized with avertin, 0.5-1.0 ml IP (20 mg/ml) ~  
67 125-240 mg/kg. 50 ul of iPS cell suspension ( $1 \times 10^6$  cells) were injected  
68 intramuscularly into the flanks (hamstring muscles) of the mice. After awaking  
69 from anesthesia, the mice were returned to their cage. After 8 weeks, the mice

70 were sacrificed by CO<sub>2</sub> euthanasia and the tumors were histologically analyzed.

71

#### 72 **4. Long-term maintenance of iPSCs**

73 iPSCs were routinely cultivated in standard hESC medium on Matrigel (BD  
74 Biosciences) -coated 6-well plates containing irradiated human feeder cells  
75 (ATCC CRL 2429). The hESC medium comprised KO DMEM/F12 supplemented  
76 with 20% Knockout Serum Replacement (Invitrogen), 10 ng/mL of bFGF  
77 (Invitrogen), 1x nonessential amino acids (Invitrogen), 0.1 mM β-Mercaptoethanol  
78 (Sigma), 1 mM L-glutamine (Gibco), plus 1% penicillin/streptomycin(Sigma). Cells  
79 were passaged every 7-9 days using 1 mg/ml collagenase IV (Invitrogen).

80

#### 81 **5. Karyotyping**

82 2×10<sup>5</sup> cells were plated and grown in a slide flask (Thermo Scientific Nunc) for 24  
83 hours. Cells were treated with 10ng/ml colcemid (Sigma-Aldrich) for 50 min. Cells  
84 were then washed twice with PBS (Ca<sup>2+</sup> and Mg<sup>2+</sup> free), followed by a serial  
85 gradient fixation at 17%, 38%, 58%, and 100% fixation solution (1:3 of acetic  
86 acid:ethanol) for 5, 5, 5, and 40 min, respectively. Slides were dried on wet filter  
87 papers at room temperature. Karyotyping was performed by mounting the slide  
88 with DAPI-antifate (0.2 µg/ul) solution followed by imaging in an Axioplan 2  
89 microscope (Leica microsystem). Images were captured with IPLab Spectrum and  
90 analyzed with Quips CGH/Karyotyper (Vysis).

#### 91 **6. Analysis of pluripotent markers in hiPS-MSCs by flow cytometry**

92 The hiPS-MSCs (passage 8 and 12) were harvested by trypsinization. Cells were

93 washed with PBS/2%FBS twice, followed by fixing with 1X FACSlysing solution  
94 for 10 min at room temperature. Fixed cells were permeabilized with FACSPERM  
95 solution for 10min at 4 °C and washed with PBS/2%FBS twice. Then cells ( $1 \times 10^6$   
96 per group) were stained with antibodies against OCT3/4 (BD Pharmingen™, Cat#  
97 560253), NANOG (BD Pharmingen™, Cat# 560791) or TRA-1-81 (BD  
98 Pharmingen™, Cat# 560793). For isotope controls, fluorochrome and  
99 concentration matched isotopes were used (IgG1 for OCT3/4 and NANOG, and  
100 IgM for TRA-1-81, BD Biosciences). Following two washes in PBS/2%FBS, cells  
101 were resuspended in 1% formaldehyde in PBS while vortex mixing. Cells were  
102 analyzed using a FACSAria™ III (BD Biosciences) equipped with a 375 nm, 488  
103 nm, 561 nm, and 633 nm laser. For each sample 30,000 cells were collected and  
104 subsequently analyzed using FlowJo software (v. 9.3.3, TreeStar Inc., Ashland,  
105 OR).

#### 106 ***7. PCL-Hyaluronan-TCP scaffold fabrication and cell seeding***

107 PCL (MW = 50 kDa, Perstorp, UK) scaffolds were made by fused deposition  
108 modeling at a processing temperature of 100 °C with a BioScaffolder (SYS + ENG  
109 GmbH, Germany). Cylindrical scaffolds with a diameter of 4 mm were punched  
110 out from a 2 mm thick porous PCL mat using a sterile biopsy punch (Acuderm,  
111 Florida). To increase surface hydrophilicity, the scaffolds were etched in 5 M  
112 sodium hydroxide for 3 hours, rinsed in sterile water multiple times, and then in  
113 70% ethanol for sterilization. For fabrication of the PCL/Hyaluronan/TCP hybrids  
114 (*PHT*), PCL scaffolds were immersed in a 4.0 mg ml<sup>-1</sup> hyaluronic acid solution  
115 (780 kDa, Lifecore Biomedical Inc., Lot P9805-9A) with  $\beta$ -TCP (Berkeley

116 advanced biomaterials Inc., Lot: TCPCH01) overnight at room temperature  
117 followed by freeze-drying (FTS, NJ, US). The weight ratio of hyaluronic acid to  
118  $\beta$ -TCP is 10:1.

119 PHT scaffolds were placed in 1% agarose-coated 24-well culture plates (one  
120 scaffold well<sup>-1</sup>). 10  $\mu$ l of an iPS-MSCs suspension ( $1.25 \times 10^7$  cells / well) was  
121 dispensed onto scaffolds, giving a seeding number of  $1.25 \times 10^5$  cells per scaffold.  
122 After 2 hours incubation, 1 ml basic medium consisting of DMEM-high glucose  
123 (Invitrogen), 2 mM L-Glutamine, 1% penicillin/streptomycin, and 10% FBS (Gibco),  
124 was added to each well and scaffolds were incubated overnight to allow the cells  
125 to adhere. In the control group, naked PCL scaffolds were seeded with  $1.25 \times 10^5$   
126 cells per scaffold. For in vitro experiments, cell-seeded scaffolds were either  
127 stimulated with osteogenic medium or cultured in basal medium throughout the  
128 study for 3 weeks. Cell/scaffold constructs were collected on days 7, 14 and 21 for  
129 DNA, ALP, calcium assay, and gene expression analysis. Cell viability on PHT  
130 scaffolds were assessed by CellTracker<sup>TM</sup> green staining on day 2 and day 7.  
131 Cellular distribution and morphology in scaffolds on day 21 were visualized in a  
132 scanning electron microscope (SEM). For in vivo experiments, cell-seeded  
133 scaffolds were pre-differentiated in osteogenic differentiation medium for 2 weeks  
134 before implantation. Media in all cultures were changed every 3-4 days.

135

### 136 **8. ALP/DNA/Calcium assay**

137 Four cellular-scaffold constructs from each group (PCL and PHT, basic and  
138 osteogenic medium) were transferred to 2 ml tubes with 400 $\mu$ l DMEM w/o Phenol

139 Red (Gibco 21063) and sonicated at intervals of 1 s on and 5 s off with amplitude  
140 of 50% (0.046 KJ) in a Bandelin Sonopuls sonicator (Buch & Holm, Denmark) for  
141 a total of 1 min. Aliquots of 60  $\mu$ l were used for ALP activity assay. The remaining  
142 volume was supplemented with 10 $\mu$ l/tube Collagenase (Sigma C8176, 100mg/ml)  
143 and incubated in a 37 °C water bath for 3 hours. Seventeen micro liter Proteinase  
144 K (Sigma P2308, 20mg/ml) and 3 $\mu$ l Pen/Strep were then added and the samples  
145 were incubated at 45 °C for 20 hrs. Scaffold debris was spun down at 10.000 x g  
146 for 5 min. Aliquots of 90  $\mu$ l were used for DNA quantification. The remaining  
147 volume was mixed with an equal volume of 1 M Acetic acid and left on a shaker  
148 overnight to dissolve the calcium deposition. The calcium amount was measured  
149 by Arsenazo III calcium assay.

150 ALP activity was determined using a colorimetric endpoint assay measuring the  
151 enzymatic conversion of P-nitrophenyl phosphate (Sigma) to the yellowish  
152 product P-nitrophenol in the presence of ALP. Absorbance of P-nitrophenol was  
153 measured in a microplate reader (Victor3 1420 Multilabel Counter, PerkinElmer  
154 Life Sciences, Denmark) at wavelengths of 405 and 600 nm. Standards were  
155 prepared from P-nitrophenol (concentration range: 0-0.2 mM). Technical  
156 duplicates were used for each biological sample. ALP activity was expressed as  
157 nmol Nitrophenol/min/ $\mu$ gDNA.

158 DNA contents were estimated by the Quant-iT™ PicoGreen® dsDNA assay  
159 (Invitrogen). Samples were diluted 1:10 in Tris–EDTA buffer. From each sample,  
160 2 x 50  $\mu$ l were drawn and suspended with 50  $\mu$ l of PicoGreen (diluted 1:200 in TE  
161 buffer). The mixtures were incubated for 5 min in the dark, and measured in a

162 96-well plate using a microplate reader (Victor3 1420 Multilabel Counter,  
163 PerkinElmer Life Sciences, Denmark). Samples were excited at 480 nm, and the  
164 fluorescence emission intensity was measured at 520 nm. Standards were  
165 prepared according to the manufacturer's instruction (lambda DNA, concentration  
166 range: 0–1 µg ml<sup>-1</sup>).

167 Calcium contents were quantified by a colorimetric endpoint assay based on the  
168 complexformation of one Ca<sup>2+</sup> ion with two Arsenazo III molecules to a  
169 blue-purple product (Diagnostic Chemicals Limited, Charlottetown, PE, Canada).  
170 The samples were diluted (1:2 on day 7 and 1:5 on day 14 and 1:10 on day 21)  
171 with double distilled water and aliquots of 20 µl were transferred to a 96-well plate.  
172 Arsenazo III solution (280 µl) was added and incubated for 10 min at room  
173 temperature. A standard dilution series of calcium ranging from 0 to 50 µg ml<sup>-1</sup>  
174 was prepared and Ca<sup>2+</sup> concentration was quantified spectrophotometrically at  
175 650 nm. Calcium content was expressed as micrograms of Ca<sup>2+</sup> per scaffold.

176

### 177 ***9. Scanning electron microscope (SEM) and confocal imaging***

178 For SEM analysis, samples were fixed in 2.5% glutaraldehyde containing 0.1 M  
179 sodium cacodylate buffer (pH 7.4) and dehydrated in a graded series of ethanol  
180 (50–99%) before being transferred to an excicator for air-drying. Constructs were  
181 analysed using a low vacuum secondary electron detector (Nova NanoSEM 600,  
182 FEI Company) and element component of cell/scaffold construct was analyzed by  
183 energy dispersive X-ray spectrometer (EDX).

184 To assess cell viability, the cell/scaffold constructs were incubated for 30 min in



185 DMEM containing 10  $\mu$ M CellTracker<sup>TM</sup> Green CMFDA (Invitrogen). The staining  
186 medium was replaced with fresh DMEM/10%FBS and the constructs were  
187 incubated for another 30 min at 37°C. The cell/scaffold constructs were then  
188 rinsed in prewarmed PBS, fixed in 10% formalin for 5 min at room temperature,  
189 and stained with 1  $\mu$ g/ml Hoechst 33258 (Sigma-Aldrich) in PBS for 20 min. Living  
190 cells were labelled green. Nuclei of the cells were stained with Hoechst, labelled  
191 red. Images were acquired using a laser scanning confocal microscope, 510 Meta  
192 (Zeiss Microimaging GmbH, Germany). The confocal settings (excitation, laser  
193 power, detector gain, and pinhole size) were same during all cell imaging.  
194 Separate channels and filters were used. Excitation/emission wavelengths were  
195 488 nm / 505-530 nm for CellTracker<sup>TM</sup> Green and 405 nm / 420 nm for Hoechst.

196

## 197 **10. Q-PCR**

198 Total RNA were isolated from cell/scaffold constructs with an RNeasy Mini Kit  
199 (Qiagen) according to the manufacturer's instructions, followed by quantification  
200 with a Nanodrop spectrophotometer and qualification by 1% agarose gel  
201 electrophoresis. Complete removal of genomic DNA from the RNA samples was  
202 achieved by treatment with DNase I (Invitrogen). For first-strand DNA synthesis,  
203 2 $\mu$ g of total RNA were reverse transcribed using a cDNA synthesis kit (Bio-Rad,  
204 Hercules, CA) in a final volume of 20  $\mu$ l. Q-PCR primers for *ALPL*, *COL1A1*, *OC*,  
205 *RUNX2*, *GAPDH*, and *BACT* are listed in **Supplementary Table 1**. One  $\mu$ l (five  
206 times diluted) cDNA was used for Q-PCR analysis. Q-PCR was performed using  
207 the LightCycle 480 SYBR Green I Mater kit on LightCycler 480 (Roche) with the

208 following PCR program: 1 hold at 95 °C for 5 min; 50 cycles at 95 °C for 10 s, 60  
209 °C for 10 s, and 72 °C for 15 s (signal acquisition once). Relative gene expression  
210 was calculated using the  $2^{-\Delta\Delta ct}$  method after normalization to the reference gene  
211 GAPDH.

212

### 213 **11. Micro-CT analysis**

214 The implants from each mouse were scanned with a high resolution micro-CT  
215 system (vivaCT 40, Scanco Medical AG, Brüttisellen, Switzerland), resulting in  
216 three-dimensional (3D) reconstruction of cubic voxel sizes  $10.5 \times 10.5 \times 10.5 \mu\text{m}^3$ .  
217 Micro-CT images were segmented using techniques described in detail previously  
218 <sup>1</sup> to obtain accurate 3D datasets of bone tissues. A mean optimal global threshold  
219 was applied to segment bone image datasets. Three-dimensional  
220 microarchitectural properties of implant bone tissue were analyzed.

221

### 222 **12. Histology analysis**

223 After micro-CT scanning, the scaffolds from each group were embedded in  
224 methylmethacrylate (MMA) and sectioned at 25- $\mu\text{m}$  thickness with a cryostat.  
225 Sections were stained with Goldener's Trichrom and Alizarin Red to visualize  
226 tissue morphology and evidence of new bone formation.

227

### 228 **13. Statistical analyses**

229 Results are presented as mean  $\pm$  standard deviation (SD). Statistic analyses were  
230 performed using Stata software. The data of ALP/DNA/calcium content and gene

231 expression were analyzed by the paired sample test. Micro CT data were  
232 analyzed with one sample mean test. Significance was set at  $P < 0.05$ .

233

#### 234 **Reference:**

235 1. Ding, M., Odgaard, A. & Hvid, I. Accuracy of cancellous bone volume fraction measured by  
236 micro-CT scanning. *Journal of biomechanics* **32**, 323-326 (1999).

237

238

239

240

#### 241 **Supplementary Figure Legends**

242

243 **Supplementary Fig. 1.** Immunostaining of OCT4, SOX2, and KLF4 expression in  
244 fibroblasts at 16 hours after modified mRNA transfection. OCT4, SOX2, and KLF4  
245 were stained in green. Nuclei were stained with DAPI (blue). Scale bar: 32  $\mu\text{m}$ .

246

247 **Supplementary Fig. 2.** ALP staining of iPS-MSCs after 7-days culturing in  
248 proliferation medium (a) or osteogenic medium (b).

249

250 **Supplementary Table 1.** List of primers used for Q-PCR

251

252 **Supplementary Table 2.** Quantitative comparison of microarchitectures between  
253 iPS-MSCs seeded scaffolds (PCL-MSC or PHT-MSC) and scaffolds without cells  
254 after implantation in nude mice for 12 weeks. BS/BV, bone surface to bone  
255 volume ratio ( $\text{mm}^{-1}$ ); BS/TV, bone surface to total volume ratio ( $\text{mm}^{-1}$ ); BV/TV,  
256 bone volume to total volume ration; SMI, structure model index; P-ratio, degree of





257 anisotropy; CD, connective density ( $\text{mm}^{-3}$ ); TbTh, trabecular thickness; TBSP,  
258 trabecular separation (mm); TbN, trabecular number. Results are given as Mean  
259 difference between iPS-MSCs seeded scaffolds (PCL-MSC or PHT-MSC) and  
260 scaffolds without cells (PCL or PHT), respectively,  $\pm$  standard deviation. The P  
261 value represents one sample mean test against zero. Significant level  $p < 0.05$ .  
262

**S Fig. 1**




YL. top

Modified mRNA





OCT4



Sox2



Klf4





0 hour

16 hour

Time Post-transfection

S Fig. 2



**Table S1**

Gene	Sequences (5'→3')	exons	Amplicon (bp)
hALPL-F	ATCAGGGACATTGACGTGATC	6-7	137
hALPL-R	TTCCAGGTGTCAACGAGGTC		
hCol1a1-F	AGGGCCAAGACGAAGACATC	1-2	138
hCol1a1-R	AGATCACGTCATCGCACAAC		
hOC-F	AGTCCAGCAAAGGTGCAGCC	2-4	169
hOC-R	TCAGCCAACCTCGTCACAGTC		
hRunx2-F	CAGTAGATGGACCTCGGGAA	5-6	188
hRunx2-R	CCTAAATCACTGAGGCGGTC		
hGAPDH-F	TGGTATCGTGGAAGGACTCATGAC	7-8	189
hGAPDH-R	ATGCCAGTGAGCTTCCCGTTCAGC		

Table S2

Parameters	Obs.	MEAN±SD	Pvalue
(OP=102)			
<b>BS/BV</b>			
PCL-MSC vs. PCL	4	13.335±24.725	0.359
PHT-MSC vs. PHT	4	-4.072±14.323	0.609
<b>BS/TV</b>			
PCL-MSC vs. PCL	4	0.689±0.673	0.133
PHT-MSC vs. PHT	4	0.751±1.158	0.285
<b>BV/TV</b>			
PCL-MSC vs. PCL	4	0.007±0.009	0.201
PHT-MSC vs. PHT	4	0.01±0.012	0.183
<b>SMI</b>			
PCL-MSC vs. PCL	4	0.125±0.193	0.285
PHT-MSC vs. PHT	4	0.49±0.839	0.326
<b>P-ratio</b>			
PCL-MSC vs. PCL	4	0.035±0.05	0.267
PHT-MSC vs. PHT	4	0.026±0.085	0.589
<b>CD</b>			
PCL-MSC vs. PCL	4	-38.221±53.435	0.247
PHT-MSC vs. PHT	4	-47.132±74.107	0.293
<b>TbTh</b>			
PCL-MSC vs. PCL	4	-0.001±0.003	0.603
PHT-MSC vs. PHT	4	-0.001±0.007	0.717
<b>TBSP</b>			
PCL-MSC vs. PCL *	4	-0.037±0.003	<0.001
PHT-MSC vs. PHT	4	-0.05±0.053	0.163
<b>TbN</b>			
PCL-MSC vs. PCL *	4	1.178±0.253	0.002
PHT-MSC vs. PHT	4	1.375±1.404	0.145